Cargando…
Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer
Cisplatin-based chemotherapy followed by radical cystectomy with bilateral pelvic lymph-node dissection is the current standard for cT2–4a N0 M0 urothelial bladder cancer. Immune checkpoint inhibitors have recently been tested in the neoadjuvant setting with promising pathological and survival resul...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317828/ https://www.ncbi.nlm.nih.gov/pubmed/34337545 http://dx.doi.org/10.1016/j.euros.2021.06.001 |